ALB and neoplasm: utilized ovarian cancer patient‐derived organoid models to create nanoparticles, Abplatin (iv), by combining Pt (IV) prodrug with human serum albumin (HSA).[299] This nanodrug not only achieved low toxicity and targeted delivery but also showed significant antitumor effects against platinum‐resistant tumor cells in ovarian cancer organoids.